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Abstract
Background: Hot flashes are a highly prevalent problem associated with menopause and breast cancer treatments.
The recent findings from the Women’s Health Initiative have important implications for the significance of a non-
hormonal, mind-body intervention for hot flashes in breast cancer survivors. Women who take hormone therapy
long-term may have a 1.2 to 2.0 fold increased risk of developing breast cancer. In addition, it is now known that
hormone therapy with estrogen and progestin is associated with increased risk of cardiovascular disease and stroke.
Currently there are limited options to hormone replacement therapy as non-hormonal pharmacological agents are
associated with only modest activity and many adverse side effects. Because of this there is a need for more
alternative, non-hormonal therapies. Hypnosis is a mind-body intervention that has been shown to reduce self-
reported hot flashes by up to 68% among breast cancer survivors, however, the use of hypnosis for hot flashes
among post-menopausal women has not been adequately explored and the efficacy of hypnosis in reducing
physiologically measured hot flashes has not yet been determined.
Methods/design: A sample of 180 post-menopausal women will be randomly assigned to either a 5-session Hypnosis
Intervention or 5-session structured-attention control with 12 week follow-up. The present study will compare hypnosis
to a structured-attention control in reducing hot flashes (perceived and physiologically monitored) in post-menopausal
women in a randomized clinical trial. Outcomes will be hot flashes (self-report daily diaries; physiological monitoring;
Hot Flash Related Daily Interference Scale), anxiety (State-Trait Anxiety Inventory; Hospital Anxiety and Depression Scale
(HADS); anxiety visual analog scale (VAS rating); depression (Center for Epidemiologic Studies Depression Scale), sexual
functioning (Sexual Activity Questionnaire), sleep quality (Pittsburgh Sleep Quality Index) and cortisol.
Discussion: This study will be the first full scale test of hypnosis for hot flashes; one of the first studies to examine
both perceived impact and physiologically measured impact of a mind-body intervention for hot flashes using
state-of-the-art 24 hour ambulatory physiological monitoring; the first study to examine the effect of hypnosis for
hot flashes on cortisol; and the first investigation of the role of cognitive expectancies in treatment of hot flashes
in comparison to a Structured-Attention Control.
Trial Registration: This clinical trial has been registered with ClinicalTrials.gov, a service of the U.S. National
Institutes of Health, ClinicalTrials.gov Identifier: NCT01293695.
Background
Hot flashes are the most common complaint of post-
menopausal women [1,2]. Almost two-thirds of post-
menopausal women have hot flashes and nearly 20% find
them to be nearly intolerable [3]. It is estimated that over
25 million women in the United States may have hot
flashes and 4 million may have severe hot flashes [4].
The experience of hot flashes can be very uncomfortable
and can have a very negative impact upon the individual’s
quality of life [5] energy and sleep [6]. It was also
reported that one-third of women with hot flashes
described embarrassment and 20% described a general
sense of a loss of control [7]. In addition, hot flashes are
associated with decreased libido [4]. Hot flashes can
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significantly decrease quality of life, alter daily activities,
and negatively affect sleep [2,8,9] in breast cancer
survivors.
The standard of care for ovarian failure and hot flashes
is hormone replacement therapy. However, estrogen
replacement therapy is a concern for some patients due
to an associated increase in the risk of breast cancer.
Cancer survivors are contraindicated for estrogen repla-
cement therapy [10]. Recent data from the Women’s
Health Initiative Trial [11], a randomized controlled trial
of hormone therapy with estrogen and progestin as pri-
mary prevention in post-menopausal women, suggest
that women who take hormone therapy long term have a
1.2 to 2.0 fold increased risk of developing breast cancer.
In the Women’s Health Initiative Trial, the incidence of
breast cancer increased by 26% for women in the estro-
gen-progestin group. In addition, hormone therapy was
shown to be associated with increased cardiovascular dis-
ease and stroke. Because of these serious concerns many
women reject estrogens [12] and health care providers
are reluctant to prescribe it. As a result, there is a need
for non-pharmacological interventions for women who
suffer from hot flashes.
Because of these concerns about hormonal interven-
tions, efforts have been made to identify non-hormonal
agents for hot flashes. Studies have been conducted to
investigate the use of: soy supplementation [13] vitamin
E [14], gabapentin [15], black cohosh and St. John’s
wort [16] and clonidine [10,17]. Soy does not seem to
be much more effective, or only modestly more effective
than placebo [4]. None of these agents have been found
to be very efficacious and can be associated with a high
toxicity profile [4,18,19].
Other studies have investigated the use of antidepres-
sant medication for hot flashes. In a pilot study of breast
cancer survivors, the use of paroxetine hydrochloride
(Paxil), showed a mean reduction of hot flashes of 67%
[4]. However, adverse reactions to the treatment included
somnolence and anxiety in 16% of the participants result-
ing in discontinuation or reduction in medication. A
pilot study to investigate the use of venlafaxine hydro-
chloride for hot flashes in cancer survivors found that the
subjects who completed the study reported a 58% reduc-
tion in hot flashes [20]. However, negative effects were
found in some participants and included symptoms of
depression, dry mouth, fatigue, sleepiness, and difficulty
with concentration. More recently, prospective rando-
mized clinical trials have confirmed these findings. Ven-
lafaxine reduced hot flashes by 60% compared to a 20%
reduction with placebo [21]. Paroxetine reduced hot
flashes by 45-65% in post-menopausal women [22,23].
Similar results were observed in breast cancer survivors
[23]. Fluoxetine decreased hot flash frequency by 50%
compared to 36% in placebo [24]. Other studies
suggested that sertraline was no more effective than pla-
cebo in decreasing hot flashes [25].
While these agents are non-hormonal and are not
thought to increase the risk of breast cancer they do have
side effects that may reduce tolerance for some patients.
Also, drug interactions can limit their use and they are not
effective for all patients, especially women on anti-estrogen
treatment. Importantly, non-hormonal agents have only
modest activity in the treatment of hot flashes and have
not been found to be as effective as hormonal therapy
[19]. Given these facts, it is imperative that effective new
interventions be developed to help post-menopausal
women who experience hot flashes.
Hypnosis has been demonstrated to be a potentially
effective treatment for hot flashes in breast cancer survi-
vors. A study was completed to evaluate the effectiveness
of hypnosis for reducing hot flashes among 16 breast
cancer survivors [26]. In this study, 16 women with a
history of hot flashes demonstrated that a hypnosis inter-
vention could achieve approximately 69% reduction in hot
flash scores relative to baseline among breast cancer survi-
vors. In this single arm pilot study we investigated the use
of hypnosis to reduce hot flashes [27]. Each patient
provided baseline data and received weekly sessions of
hypnosis that followed a standardized transcript that
allowed for individualization of mental imagery for relaxa-
tion and coolness. Throughout the clinical care, partici-
pants completed daily diaries of the frequency and severity
of their hot flashes. The hot flash score, a measure of
severity and frequency, was determined by multiplying the
daily frequency of hot flashes by their average severity.
Results indicated a 58.6% decrease in total daily hot flashes
and a 69.8% decrease in weekly hot flash scores from their
baselines. Based upon our initial findings we then com-
pleted a second study under the auspices of an R-21 grant.
In this study breast cancer survivors with hot flashes were
randomized to either a therapist delivered hypnosis inter-
vention or a wait-list control condition. Participants in the
hypnosis intervention received 5 sessions of individual
hypnosis delivered by a trained hypnotherapist and with
individualization of mental imagery for coolness [28].
Results demonstrate that by the end of the treatment per-
iod, hot flash scores (frequency × average severity)
decreased 68% from baseline to endpoint in the hypnosis
arm (p < .001). Also, significant improvements in self-
reported anxiety, depression, interference of hot flashes on
daily activities, and sleep were observed for patients who
received the hypnosis intervention (p < .005) in compari-
son to the no-treatment control group.
Methods/design
Subjects
A total of approximately 180 post-menopausal women
will be entered into the study. A screening checklist will
Elkins et al. BMC Complementary and Alternative Medicine 2011, 11:92
http://www.biomedcentral.com/1472-6882/11/92
Page 2 of 8
be used to determine eligibility. Participants will be ran-
domly assigned to either a hypnosis intervention or
structured-attention control.
Eligibility Criteria
Eligibility criteria were developed in reference to the
Department of Health and Human Services, Food and
Drug Administration (FDA) draft recommendations [29],
research guidelines [30,31]. Postmenopausal as defined
by 1) no menstrual period in the past 12 months; 2) no
menstrual period in the past 6 months and a medically
documented history of FSH level greater than 40; or 3)
women who have had a bilateral oophorectomy. If
women have had a hysterectomy and still have their ovar-
ies, they must meet the FSH criteria described above. A
participant is eligible if they have a self-reported history
of a minimum of 7 hot flashes per day or 50 hot flashes
per week at baseline, aged over 18 years and ability to
give her own consent for participation in the study, and
have discontinued other putative therapies for hot flashes
for at least one month prior to enrollment (however,
because many of the participants seen in our institutions
take vitamin preparations, Vitamin E will be allowed).
Further, we participants must be able to attend weekly
sessions.
Exclusion Criteria
Participants will be excluded from participation if they
are receiving other simultaneous treatment for hot
flashes, or using any CAM (Complementary and Alterna-
tive Medicine) treatments for vasomotor symptoms. This
would include soy products and other phytoestrogens,
black cohosh, and any mind-body techniques including
meditation and yoga, etc. Further, participants will be
excluded if they have any medical or psychiatric condi-
tion that in the opinion of the investigator puts the parti-
cipant at potential risk during the study, are currently
using hypnosis for any reason, or have an inability to
speak or understand English.
Randomization
After the 7-day baseline data have been collected, partici-
pants may return the completed daily diary, Biolog® 3991
monitor, Bahr monitor and cortisol samples. Between
week 0 and week 1 visits, the Research Coordinator will
contact the Data Coordinator who will provide random
assignment for the participant, and this assignment will be
placed in a sealed envelope that will not be opened until
the visit at week 1. Random assignment will be made
sequentially from a confidential computer-generated list of
permuted blocks of varying size. The list is generated to
provide equal probabilities to the study arms. The study
participants will be randomly assigned by the Data Coordi-
nator to either the hypnosis intervention or to a
structured-attention control group. An overview of the
chronology of the study is provided graphically [Figure 1].
Experimental Intervention
Participants assigned to the hypnosis intervention will be
scheduled to meet with a hypnosis research therapist for
five visits. All visits will follow eight key components of
structured attention guidelines as defined in the treat-
ment manual. In addition, participants in the Hypnosis
Intervention will receive a hypnotic induction at each
session and a CD recording of a hypnotic induction. The
hypnotic induction will follow a well-defined standard
transcript but will include mental imagery for relaxation
and coolness based on preferences of the participant and
encouragement to practice hypnosis on a daily basis with
and without the recording.
At the first session the hypnosis research therapist will
provide the participant with a handout regarding hot
flashes with a hypnosis related description. The use of hyp-
nosis will be discussed and the participant will be provided
with information regarding hypnosis. Each participant will
be provided with a brief discussion regarding myths and
misconceptions about hypnosis and the process used in
hypnotic induction [31]. The participants will also be asked
to rate their level of anxiety at the beginning of the session
and after the hypnotic induction. The research therapist
will review a checklist, contained in the treatment manual
at each treatment session to ensure consistency.
Participants will be scheduled to return on an approxi-
mately weekly basis for sessions 2-5. Each session will
include a hypnotic induction and during session 3, a hand-
out with step-by-step instructions in self-hypnosis will be
presented. The research therapist will ask the participants
about their use of self-hypnosis and their preferences of
self-hypnosis (i.e., with the self-hypnosis recording or
without using the recording). The research therapist will
also discuss the frequency and severity of the participants’
hot flashes, and inquire about the effectiveness of self-
hypnosis in decreasing the frequency and severity of the
hot flashes on a daily basis. Participants will be asked to
identify specific imagery for relaxation and imagery for
coolness in order to individualize the hypnotic induction
based upon the participants’ preferences [32].
Control Intervention
The structured-attention control condition is designed to
control for attention, monitoring symptoms, and inter-
personal exchange that is inherent in therapeutic hypno-
sis intervention. In designing our structured-attention
control condition we followed the recommendations of
Jensen and Patterson [33] that has determined the impor-
tance of creating control conditions that include mini-
mal-effect interventions and that are well defined. All
visits will follow structured attention guidelines as
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defined in the treatment manual. The structured atten-
tion guidelines will follow eight key components devel-
oped specifically for this study. This type of approach
(with somewhat different key components for pain con-
trol) has previously been used in the study of hypnosis
with medical participants [34].
Participants assigned to the structured-attention con-
trol condition will meet with a research therapist for five
individual approximately weekly visits. The eight key
components will be: Information (i.e. causes of hot
flashes, triggers for hot flashes); monitoring of hot flashes
(i.e. “How many hot flashes did you have yesterday?;
Figure 1 Study Design.
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“How severe were your hot flashes yesterday?”); rating
anxiety (i.e. “Please rate how anxious you feel.”); attentive
listening; interpersonal exchange; discussion of symp-
toms (i.e. “How have you been feeling during the past
week?”: “How have you been sleeping?”); encouragement
(i.e. “You are doing well.”); and avoidance of negative
suggestion. Also, at the first session the research therapist
will provide the participant with a handout regarding hot
flashes without mention of hypnosis. In addition, partici-
pants in the structured-attention control condition will
be provided with a CD recording that they can listen to
at home. The recording will be approximately the same
length of time as the hypnosis recording that those in the
hypnosis group will receive, however no hypnotic induc-
tion will be provided to the Structured-Attention Con-
trol. The research therapist will review a checklist at each
intervention session to assure consistency contained in
the treatment manual.
Effect Measures
Outcomes will be hot flashes (self-report daily diaries; phy-
siological monitoring; Hot Flash Related Daily Interference
Scale), anxiety (State-Trait Anxiety Inventory; Hospital
Anxiety and Depression Scale (HADS); anxiety visual ana-
log scale (VAS rating); depression (Center for Epidemiolo-
gic Studies Depression Scale), sexual functioning (Sexual
Activity Questionnaire), sleep quality (Pittsburgh Sleep
Quality Index) and cortisol; moderators will be cognitive
expectancies (VAS ratings) and hypnotizability (Stanford
Hypnotic Susceptibility Scale-Form C). A figure represent-
ing the schedule of collection is provided [Figure 2].
Hot Flashes via Sternal Skin Conductance Monitoring
Two different sternal skin conductance monitoring
systems may be used to objectively measure hot flash fre-
quency. With the Biolog® ambulatory recorder [35], skin
conductance levels are monitored using Medi-Trace
silver/silver chloride and a 0.5 constant voltage circuit
[36]. Electrodes are 1.5 cm in diameter and filled with 0.05
M potassium chloride Velvachol/glycol gel [37]. Electrodes
are attached 1.5” below the collarbones and 2” on either
side of the sternal mid-line. Participants will be educated
on the proper use of the monitor. The Biolog® monitor is
a solid-state device containing a microprocessor and 4
megabytes (MB) of memory. The 3991 was designed by
the company with input from the study Consultant, Dr.
Carpenter, to provide (1) a smaller and more lightweight
hot flash monitor and (2) capability for storing 24 hours’
worth of data.
The Bahr Hot Flash Monitor [38] may be used to mea-
sure objective hot flashes in conjunction with the Biolog®
monitor. The Bahr monitor attaches to a 1” × 2” cloth
patch that contains the two electrodes to be placed in the
midline over the sternum, two to three inches below the
sternoclavicular notch. Prior to connection with the elec-
trodes, the monitor should be synchronized and time
stamped with the Bahr watch and software. The monitor
should then be activated using a magnet until the green
light flashes. The activation time and the attachment
time should be recorded in the Monitor Log. When the
participant subjectively observes a hot flash, they will be
instructed to pass the magnet close to the monitor and a
red light will flash to indicate acceptance of the marker.
The monitor will measure skin conductance every ten
seconds. The participant may wear the monitor for
simultaneous comparison with the Biolog® monitor. One
advantage of the Bahr monitor is that the dimensions are
much smaller than the Biolog® (6 × 2 × 1 cm) and is
light enough to simply hang from the chest leads without
carrying an extra bag to store the device.
Salivary cortisol
Salivary cortisol samples will be collected four times in the
same day by participants during the week before the first
Figure 2 Data Collection Schedule.
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session (baseline) and after completing approximately
five sessions of the hypnosis intervention or structured-
attention control. Instructions will be provided to partici-
pants upon receipt of the cortisol materials. Pre- and post-
session salivary cortisol samples will also be collected at
the participants’ first session with the research therapist.
Salivary cortisol samples will be assayed with a time-
resolved immunoassay with a cortisolbiotin conjugate as a
tracer. Total cortisol produced over a day will be measured
by calculating the area-under-the-curve (AUC). This
represents the total volume of cortisol secretion over the
day. We will also examine cortisol levels at each time
point averaged across the areas under the curve and mean
diurnal and nocturnal levels will be compared and the pre-
sence of circadian rhythmicity will be evaluated [39].
Statistical power and Sample size
Power analyses were conducted using the partial eta-
squared (hp
2) from the repeated measures ANOVAs run
for the pilot study. Analyses were based on a sample size
of 180 (90 per arm) with a conservative estimate of 30%
drop-out. Further, it is recognized that there is the possibi-
lity of a placebo effect not observed in the pilot study due
to the provision of an active control group. Placebo effects
of as large as a 30% reduction in hot flash frequencies and
hot flash severity scores have been reported (Sloan et al.,
2001). Thus, the calculations reported here are based on a
sample size of 126 with effect sizes 30% smaller than those
from the pilot study.
An overall experiment-wise alpha of 0.05 will be used,
with a Dunn/Bonferroni correction to adjust the error rate
for individual analyses. Twenty-one separate analyses are
planned (8 for Aim 1, 8 for Aim 2, 5 for Aim 3). Thus,
these sample size calculations are based on a = 0.00238
(0.05/21).
Power calculations were conducted using pilot data,
analyzed using repeated measures ANOVAs with one
between-subjects and one within-subjects variable. Cal-
culations were conducted using G*Power and focused
on the interaction term from these analyses. G*Power
takes into account the expected effect size (hp
2, reduced
by 30%), alpha (0.00238), desired power (0.90), correla-
tion between pre- and post-test, and sphericity. The
sample size needed for 0.90 power based on these calcu-
lations (CES-D, hp
2 = 0.0672, r = 0.492, pre-post) was
72 (sample size calculations using other dependent vari-
ables were smaller). Given a sample size of 180, with a
30% drop out/missing data rate, power would be 0.99
for this comparison. Thus, this study is adequately pow-
ered even if a higher than anticipated drop out rate
occurs, or if missing data reduces the N for some of the
analyses.
Participant demographic characteristics will be ana-
lyzed using descriptive statistics, including baseline
characteristics, averages, and related confidence inter-
vals. Hot flash scores and frequencies will be plotted
over the study period. The hot-flash score, being a mea-
sure of severity and frequency, is determined by multi-
plying the daily frequency of hot flashes by their severity
(Perez et al., 2004). Analysis will be completed to
fully examine and explore the data and to test the
hypotheses.
Primary analyses will be conducted using a mixed
model approach, with each dependent variable analyzed
separately as a pretest-posttest control group design
with one within-subjects variable (pre-post) and one
between-subjects variable (experimental-control). Com-
posites will be used for analyses with multiple scales
(e.g., a single sleep composite will be used).
Data Quality and Data Monitoring
All data (with the exception of VAS ratings of anxiety, and
pre and post measurements of resting heart rate and
blood pressure) will be collected by the Research Coordi-
nator and Data Coordinator separate from the therapists
providing intervention. The Data Coordinator will oversee
data entry. To assure quality, data will be entered into a
data base twice by doctoral Students in Psychology at
Baylor University or other assigned personnel who will be
blinded as to the participants’ assignment. The data will
then be sent to a biostatistician and checked for consis-
tency and completeness. Any inconsistency or incomplete-
ness will be addressed by the Research Coordinator, Data
Coordinator and PI for accuracy. A data safety and moni-
toring plan has been developed for this study. The P.I. in
conjunction with the biostatistician or other assigned per-
sonnel will check the data for completeness and quality on
a quarterly basis. Once the data has been entered into a
data base and data quality has been assured the data base
will be subjected to further analyses. As required by
NCCAM/NIH, a DSMB will be selected and will periodi-
cally review the adverse events and the collected data.
Within the 5 year study duration, we expect the DSMB to
meet at least annually. The meetings will serve to establish
whether the study is accruing appropriately, whether the
data collection is running smoothly, whether unexpected
toxicities are present, and whether patients are completing
both phases of the study. At a minimum, the DSMB will
meet at least annually and within 7 days of any serious
adverse events.
Ethical Review
The study protocol ID# 194610-8, “Hypnosis for Hot
Flashes Among Postmenopausal Women in a Randomized
Clinical Trial” received ethical review from the Baylor Uni-
versity Institutional Review Board and was approved April
1, 2011, signed by Michael E. Sherr, Ph.D., Chair of the
Baylor Institutional Review Board, available by phone at
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00 1 512 710-4483, or by email at michael_sherr@baylor.
edu.
Current Status of Trial
This trial is currently in accrual at the time this manu-
script was prepared. To date, there are no other manu-
scripts under submission nor published based on this
trial.
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